Literature DB >> 17701658

Testosterone therapy in the aging male.

Bruno Lunenfeld1, Eberhard Nieschlag.   

Abstract

The decline, with aging, in serum concentrations of biologically active forms of testosterone in men is an indisputable fact and some men will eventually develop symptoms of late-onset hypogonadism (LOH) with its clinical consequences. LOH reduces quality of life and may pose important risk factors for frailty, changes in body composition, cardiovascular disease, sexual dysfunction and osteoporosis. Testosterone supplementation in cases of LOH will restore serum testosterone levels into the physiologic range; will restore metabolic parameters to the eugonadal state, increase muscle mass, strength, and function; maintaine or improve BMD reducing fracture risk; will improve neuropsychological function (cognition and mood); libido and sexual functioning; and enhance quality of life. The ultimate goals, however, are to maintain or regain a high quality of life, to reduce disability, to compress major illnesses into a narrow age range and to add life to years. To achieve these goals men must also adjust their lifestyle to optimize dietary habits, as well as to exercise and to abstain from smoking life-long. Monitoring these patients is a shared responsibility that cannot be taken lightly. The physician must emphasize to the patient the need for periodic evaluations and the patient must agree to comply with these requirements. The physician's evaluation should include an assessment of the clinical response and monitoring must be tailored to the indications and individual needs of the patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17701658     DOI: 10.1080/13685530701485998

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  11 in total

1.  Differentiation of umbilical cord mesenchymal stem cells into steroidogenic cells in comparison to bone marrow mesenchymal stem cells.

Authors:  X Wei; G Peng; S Zheng; X Wu
Journal:  Cell Prolif       Date:  2012-02-13       Impact factor: 6.831

Review 2.  Androgens and male aging: Current evidence of safety and efficacy.

Authors:  Louis J Gooren
Journal:  Asian J Androl       Date:  2010-02-15       Impact factor: 3.285

3.  Effect of Testosterone Replacement Therapy on Cognitive Performance and Depression in Men with Testosterone Deficiency Syndrome.

Authors:  Hyun Jin Jung; Hong Seok Shin
Journal:  World J Mens Health       Date:  2017-01-23       Impact factor: 5.400

Review 4.  The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health.

Authors:  Marià Alemany
Journal:  Int J Mol Sci       Date:  2022-10-08       Impact factor: 6.208

5.  [Testosterone substitution with special regard to prostate cancer].

Authors:  M Beintker; H Behre
Journal:  Urologe A       Date:  2008-12       Impact factor: 0.639

Review 6.  To treat or not to treat with testosterone replacement therapy: a contemporary review of management of late-onset hypogonadism and critical issues related to prostate cancer.

Authors:  Bruce R Kava
Journal:  Curr Urol Rep       Date:  2014-07       Impact factor: 3.092

7.  Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy.

Authors:  Prasanth N Surampudi; Christina Wang; Ronald Swerdloff
Journal:  Int J Endocrinol       Date:  2012-03-14       Impact factor: 3.257

8.  Differential alterations in gene expression profiles contribute to time-dependent effects of nandrolone to prevent denervation atrophy.

Authors:  Weiping Qin; Jiangping Pan; William A Bauman; Christopher P Cardozo
Journal:  BMC Genomics       Date:  2010-10-22       Impact factor: 3.969

9.  Diagnosis and treatment of sexual dysfunctions in late-onset hypogonadism.

Authors:  Jin Wook Kim; Du Geon Moon
Journal:  Korean J Urol       Date:  2011-11-17

10.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.